Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $32.00.

A number of research firms have commented on CPRX. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research report on Thursday, May 7th.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals in the third quarter valued at approximately $39,000. Quarry LP acquired a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at about $40,000. Clearstead Advisors LLC grew its position in shares of Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 1,167 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares during the period. Finally, Financial Life Planners bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $42,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $31.47 on Friday. Catalyst Pharmaceuticals has a 12 month low of $19.05 and a 12 month high of $32.56. The stock has a 50-day moving average price of $31.18 and a 200 day moving average price of $26.73. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 0.96 and a beta of 0.74.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).